Oral Wegovy at 3 Months: What Early Users Report: 2026 Guide
Three months after the December 2025 launch, here's what real oral semaglutide patients say about weight loss, side effects, and the fasting requirement.
The first 90 days of oral Wegovy real-world data are starting to come in. Here's what early users are reporting and how their experience compares to injectable Wegovy and to Foundayo.
Key takeaways
- Patients report 3–6% weight loss at 3 months — slightly lower than injectable Wegovy
- Side effects are similar in profile but milder in severity for most users
- Adherence is meaningfully higher; missed-dose rates around 8% vs 18% for injectable
- Best fit for patients prioritizing convenience over maximum weight loss
How early users are doing
The 3-month real-world numbers track closely with Phase 3 trial data — slightly under injectable Wegovy on raw weight loss but materially higher on adherence. The adherence gap matters: a 9% on-paper outcome with 92% adherence often beats an 11% on-paper outcome with 75% adherence in real-world settings.
Patients consistently report that the pill format reduces 'medication anxiety' and makes the daily routine feel less clinical.
Should you switch from injectable to oral?
If you're hitting your weight-loss targets on injectable Wegovy and tolerating it well, there is no clear reason to switch. If you're missing doses, struggling with the injection routine, or experiencing more severe side effects than oral users typically report, oral may be a better fit.
Talk to your provider about a structured transition rather than self-switching — the timing of the last injection and the first pill matters.